Oculis Holding AG...announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada. (GlobeNewswire) - Jun 13, 2026 - "The presentation will highlight the development journey of Privosegtor, a peptoid small molecule that can cross both the blood-brain and retinal barriers and has the potential to become the first neuroprotective therapy for optic neuritis (ON), with potential broad applicability in other neuro-ophthalmic and neurological diseases....Following the successful Phase 2 ACUITY trial and the granting of Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for ON and PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA), Oculis is advancing the PIONEER registrational program for Privosegtor in optic neuropathies, with the PIONEER-1 trial in optic neuritis....Privosegtor is currently being evaluated in Oculis' PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials..."
Clinical • Optic Neuritis
|